T. Mestre, J. Ferreira, M. M. Coelho, M. Rosa, and C. Sampaio, Therapeutic interventions for symptomatic treatment in Huntington's disease, Cochrane Database Syst Rev, vol.8, p.6456, 2009.

C. A. Ross and S. J. Tabrizi, Huntington's disease: from molecular pathogenesis to clinical treatment, Lancet Neurol, vol.10, pp.83-98, 2011.

C. S. Venuto, A. Mcgarry, Q. Ma, and K. Kieburtz, Pharmacologic approaches to the treatment of Huntington's disease, Mov Disord, vol.27, pp.31-41, 2012.

M. J. Armstrong and J. M. Miyasaki, Evidencebased guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology, Neurology, vol.79, pp.597-603, 2012.

A. Killoran and K. M. Biglan, Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?, Mov Disord, vol.29, pp.1404-1417, 2014.

J. Priller, D. Ecker, B. Landwehrmeyer, and D. Craufurd, A Europe-wide assessment of current medication choices in Huntington's disease, Mov Disord, vol.23, p.1788, 2008.

J. Burgunder, M. Guttman, S. Perlman, N. Goodman, D. P. Van-kammen et al., An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease, PLoS Curr, vol.3, 2011.

J. S. Paulsen, A. C. Miller, T. Hayes, and E. Shaw, Cognitive and behavioral changes in Huntington disease before diagnosis, Handb Clin Neurol, vol.144, pp.69-91, 2017.

H. Study-group, Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial, Neurology, vol.66, pp.366-72, 2006.

J. Deroover, F. Baro, R. P. Bourguignon, and P. Smets, Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea, Curr Med Res Opin, vol.9, pp.329-367, 1984.

N. Quinn and C. D. Marsden, A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia, J Neurol Neurosurg Psychiatry, vol.47, pp.844-851, 1984.

N. A. Van-de-zande, T. H. Massey, D. Mclauchlan, P. Roberts, A. Zutt et al., Clinical characterization of dystonia in adult patients with Huntington's disease, Eur J Neurol, vol.24, pp.1140-1147, 2017.

A. Barbeau, L-dopa and juvenile Huntington's disease, Lancet, vol.2, p.1066, 1969.

P. A. Low, J. L. Allsop, and G. M. Halmagyi, Huntington's chorea: the rigid form (Westphal variant) treated with levodopa, Med J Aust, vol.1, pp.393-397, 1974.

I. Reuter, M. T. Hu, T. C. Andrews, D. J. Brooks, C. Clough et al., Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome, J Neurol Neurosurg Psychiatry, vol.68, pp.238-279, 2000.

A. P. Vargas, F. J. Carod-artal, D. Bomfim, C. Vázquez-cabrera, and C. Dantas-barbosa, Unusual early-onset Huntingtons disease, J Child Neurol, vol.18, pp.429-461, 2003.

P. J. Jongen, W. O. Renier, and F. J. Gabreëls, Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic-rigid form, Clin Neurol Neurosurg, vol.82, pp.251-61, 1980.

S. Wang, L. Wang, C. Chen, C. Tang, L. Wu et al., Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease, Mov Disord, vol.19, pp.854-860, 2004.

L. Quinn and M. Busse, Physiotherapy clinical guidelines for Huntington's disease, Neurodegener Dis Manage, vol.2, pp.21-31, 2012.

S. Frank, Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators, BMC Neurol, vol.9, p.62, 2009.

C. Y. Huang, J. G. Mcleod, R. T. Holland, and C. Elliot, Tetrabenazine in the treatment of Huntington's chorea, Med J Aust, vol.1, pp.583-587, 1976.

A. D. Monaco, A. Nuzzi, A. Parente, V. Lavermicocca, T. Chiarelli et al., I03 swallowing function in the early, middle and late stages of Huntington's disease, J Neurol Neurosurg Psychiatry, p.58, 2014.

M. C. Kagel and N. A. Leopold, Dysphagia in Huntington's disease: a 16-year retrospective, Dysphagia, vol.7, pp.106-120, 1992.

C. Giddens, E. A. Coleman, and C. Adams, Home program of speech therapy in Huntington's disease, J Med Speech Lang Pathol, vol.18, pp.1-9, 2010.

F. Carella, V. Scaioli, C. Ciano, S. Binelli, D. Oliva et al., Adult onset myoclonic Huntington's disease, Mov Disord, vol.8, pp.201-206, 1993.

S. Novom, S. Danna, and M. A. Goldberg, Intention myoclonus in Huntington's disease, Bull Los Angeles Neurol Soc, vol.41, pp.82-86, 1976.

P. Previdi and R. Borgonovi, Myoclonus and Huntington's chorea: description of a case, Ital J Neurol Sci, vol.1, pp.189-91, 1980.

C. Saft, T. Lauter, P. H. Kraus, H. Przuntek, and J. E. Andrich, Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's disease patients: a case series, BMC Neurol, vol.6, p.11, 2006.

P. D. Thompson, K. P. Bhatia, P. Brown, M. B. Davis, M. Pires et al., Cortical myoclonus in Huntington's disease, Mov Disord, vol.9, pp.633-674, 1994.

C. M. Vogel, I. Drury, L. C. Terry, and A. B. Young, Myoclonus in adult Huntington's disease, Ann Neurol, vol.29, pp.213-218, 1991.

M. E. Landau and K. R. Cannard, EEG characteristics in juvenile Huntington's disease: a case report and review of the literature, Epileptic Disord, vol.5, pp.145-153, 2003.

S. Kereshi, R. E. Schlagenhauff, and K. S. Richardson, Myoclonic and major seizures in early adult Huntington's chorea: case-report and electro-clinical findings, Clin Electroencephalogr, vol.11, pp.44-51, 1980.

A. K. Rao, L. Muratori, E. D. Louis, C. B. Moskowitz, and K. S. Marder, Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease, Mov Disord, vol.23, pp.1100-1107, 2008.

A. Delval, P. Krystkowiak, J. Blatt, M. Delliaux, A. Destée et al., Evolution of locomotion disorders in Huntington's disease, Neurophysiol Clin, vol.38, pp.117-142, 2008.

P. Zinzi, D. Salmaso, D. Grandis, R. Graziani, G. Maceroni et al., Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study, Clin Rehabil, vol.21, pp.603-616, 2007.

A. Piira, M. R. Van-walsem, G. Mikalsen, K. H. Nilsen, S. Knutsen et al., Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington's disease: a prospective intervention study, PLoS Curr, vol.5, 2013.

A. Piira, M. R. Van-walsem, G. Mikalsen, L. Øie, J. C. Frich et al., Effects of a two-year intensive multidisciplinary rehabilitation program for patients with Huntington's disease: a prospective intervention study, PLoS Curr, vol.6, 2014.

D. Kegelmeyer, N. Fritz, S. Kostyk, and A. Kloos, J04 The effect of video game-based exercise on dynamic balance and mobility in individuals with Huntington's disease, J Neurol Neurosurg Psychiatry, p.40, 2010.

M. Busse, L. Quinn, K. Debono, K. Jones, J. Collett et al., A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease, J Neurol Phys Ther, vol.37, pp.149-58, 2013.

L. Quinn, K. Debono, H. Dawes, A. E. Rosser, A. H. Nemeth et al., Task-specific training in Huntington disease: a randomized controlled feasibility trial, Phys Ther, vol.94, pp.1555-68, 2014.

I. Ciancarelli, T. Ciancarelli, M. G. Carolei, and A. , Effectiveness of intensive neurorehabilitation in patients with Huntington's disease, Eur J Phys Rehabil Med, vol.49, pp.189-95, 2013.

H. Khalil, L. Quinn, R. Van-deursen, H. Dawes, R. Playle et al., What effect does a structured home-based exercise programme have on people with Huntington's disease? A randomized, controlled pilot study, Clin Rehabil, vol.27, pp.646-58, 2013.

M. H. Thaut, R. Miltner, H. W. Lange, C. P. Hurt, and V. Hoemberg, Velocity modulation and rhythmic synchronization of gait in Huntington's disease, Mov Disord, vol.14, pp.808-827, 1999.

S. Bohlen, C. Ekwall, K. Hellström, H. Vesterlin, M. Björnefur et al., Physical therapy in Huntington's disease-toward objective assessments?, Eur J Neurol, vol.20, pp.389-93, 2013.

E. Mirek, M. Filip, K. Banaszkiewicz, M. Rudzinska, J. Szymura et al., The effects of physiotherapy with PNF concept on gait and balance of patients with Huntington's disease -pilot study, Neurol Neurochir Pol, vol.49, pp.354-361, 2015.

R. M. Bonelli, F. A. Mahnert, and G. Niederwieser, Olanzapine for Huntington's disease: an open label study, Clin Neuropharmacol, vol.25, pp.263-268, 2002.

R. M. Bonelli, G. Niederwieser, G. G. Tribl, and P. Költringer, High-dose olanzapine in Huntington's disease, Int Clin Psychopharmacol, vol.17, pp.91-94, 2002.

A. Ciammola, J. Sassone, C. Colciago, N. E. Mencacci, B. Poletti et al., Aripiprazole in the treatment of Huntington's disease: a case series, Neuropsychiatr Dis Treat, vol.5, pp.1-4, 2009.

M. R. Knowling and W. Wrench, Treatment of Huntington's chorea with sulpiride, S Afr Med J, p.169, 1991.

A. D. Kloos, D. A. Kegelmeyer, S. E. White, and S. K. Kostyk, The impact of different types of assistive devices on gait measures and safety in Huntington's disease, PLoS ONE, vol.7, p.30903, 2012.

M. C. Nash, R. B. Ferrell, M. A. Lombardo, R. Williams, E. K. Tan et al., Treatment of bruxism in Huntington's disease with botulinum toxin, J Neuropsychiatry Clin Neurosci, vol.16, pp.171-174, 2000.

D. L. Mclellan, R. J. Chalmers, and R. H. Johnson, A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea, Lancet, vol.1, pp.104-111, 1974.

R. E. Ready, M. Mathews, A. Leserman, and J. S. Paulsen, Patient and caregiver quality of life in Huntington's disease, Mov Disord, vol.23, pp.721-727, 2008.

T. M. Cruickshank, J. A. Thompson, D. Domínguez, A. P. Reyes, M. Bynevelt et al., The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study, Brain Behav, vol.5, p.312, 2015.

C. Metzler-baddeley, J. Cantera, E. Coulthard, A. Rosser, D. K. Jones et al., Improved executive function and callosal white matter microstructure after rhythm exercise in Huntington's disease, J Huntingtons Dis, vol.3, pp.273-83, 2014.

M. Papoutsi, I. Labuschagne, S. J. Tabrizi, and J. C. Stout, The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation, Mov Disord, vol.29, pp.673-83, 2014.

C. L. Ludlow, N. P. Connor, and C. J. Bassich, Speech timing in Parkinson's and Huntington's disease, Brain Lang, vol.32, pp.90124-90130, 1987.

C. Saldert, A. Fors, S. Ströberg, and L. Hartelius, Comprehension of complex discourse in different stages of Huntington's disease, Int J Lang Commun Disord, vol.45, pp.656-69, 2010.

U. Ferm, A. Sahlin, L. Sundin, and L. Hartelius, Using talking mats to support communication in persons with Huntington's disease, Int J Lang Commun Disord, vol.45, pp.523-559, 2010.

E. Bora, D. Velakoulis, and M. Walterfang, Social cognition in Huntington's disease: a meta-analysis, Behav Brain Res, vol.297, 2016.

E. Aretouli and J. Brandt, Episodic memory in dementia: characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases, Arch Clin Neuropsychol, vol.25, pp.396-409, 2010.

C. Beste, C. Saft, J. Andrich, T. Müller, R. Gold et al., Time processing in Huntington's disease: a group-control study, PLoS ONE, vol.2, p.1263, 2007.

A. K. Rao, K. S. Marder, J. Uddin, and B. C. Rakitin, Variability in interval production is due to timing-dependent deficits in Huntington's disease, Mov Disord, vol.29, pp.1516-1538, 2014.

T. E. Cope, M. Grube, B. Singh, D. J. Burn, and T. D. Griffiths, The basal ganglia in perceptual timing: timing performance in Multiple System Atrophy and Huntington's disease, Neuropsychologia, vol.52, pp.73-81, 2014.

A. D. Lawrence, L. H. Watkins, B. J. Sahakian, J. R. Hodges, and T. W. Robbins, Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits, Brain, pp.1349-64, 2000.

S. Martinez-horta, J. Perez-perez, E. Van-duijn, R. Fernandez-bobadilla, M. Carceller et al., Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease, Parkinsonism Relat Disord, vol.25, pp.58-64, 2016.

E. Van-duijn, D. Craufurd, A. Hubers, E. J. Giltay, R. Bonelli et al., Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY), J Neurol Neurosurg Psychiatry, vol.85, pp.1411-1419, 2014.

E. A. Epping, J. A. Mills, L. J. Beglinger, J. G. Fiedorowicz, D. Craufurd et al., Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study, J Psychiatr Res, vol.47, pp.1423-1454, 2013.

L. J. Beglinger, W. H. Adams, D. Langbehn, J. G. Fiedorowicz, J. R. Biglan et al., Results of the citalopram to enhance cognition in Huntington disease trial, Mov Disord, vol.29, pp.401-406, 2014.

C. F. Lewis, J. R. Dequardo, and R. Tandon, ECT in genetically confirmed Huntington's disease, J Neuropsychiatry Clin Neurosci, vol.8, pp.209-219, 1996.

N. G. Ranen, C. E. Peyser, and S. E. Folstein, ECT as a treatment for depression in Huntington's disease, J Neuropsychiatry Clin Neurosci, vol.6, pp.154-163, 1994.

D. L. Evans, C. A. Pedersen, and M. E. Tancer, ECT in the treatment of organic psychosis in Huntington's disease, Convuls Ther, vol.3, pp.145-50, 1987.

M. Wesson, N. R. Boileau, J. S. Perlmutter, J. S. Paulsen, S. K. Barton et al., Suicidal ideation assessment in individuals with premanifest and manifest Huntington disease, J Huntingtons Dis, vol.7, pp.239-288, 2018.

J. G. Fiedorowicz, J. A. Mills, A. Ruggle, D. Langbehn, and J. S. Paulsen, PREDICT-HD Investigators of the Huntington Study Group. Suicidal behavior in prodromal Huntington disease, Neurodegener Dis, vol.8, pp.483-90, 2011.

E. Van-duijn, E. M. Kingma, and R. C. Van-der-mast, Psychopathology in verified Huntington's disease gene carriers, J Neuropsychiatry Clin Neurosci, vol.19, pp.441-449, 2007.

N. G. Ranen, J. R. Lipsey, G. Treisman, and C. A. Ross, Sertraline in the treatment of severe aggressiveness in Huntington's disease, J Neuropsychiatry Clin Neurosci, vol.8, pp.338-378, 1996.

N. De-marchi, D. F. Ragone, and M. A. , Fluoxetine in the treatment of Huntington's disease, Psychopharmacology (Berl), vol.153, pp.264-270, 2001.

G. Désaméricq, G. Dolbeau, C. Verny, P. Charles, A. Durr et al., Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort, Neurology, vol.9, pp.1023-1027, 1995.

T. G. Johnston, Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms, Int Clin Psychopharmacol, vol.26, pp.114-123, 2011.

V. E. Grove, J. Quintanilla, and G. T. Devaney, Improvement of Huntington's disease with olanzapine and valproate, N Engl J Med, vol.343, pp.973-977, 2000.

Y. Shen, Lamotrigine in motor and mood symptoms of Huntington's disease, World J Biol Psychiatry, vol.9, pp.147-156, 2008.

R. Levy and V. Czernecki, Apathy and the basal ganglia, J Neurol, pp.54-61, 2006.

J. A. Bouwens, E. Van-duijn, R. C. Van-der-mast, R. Roos, and E. J. Giltay, Irritability in a prospective cohort of Huntington's disease mutation carriers, J Neuropsychiatry Clin Neurosci, vol.27, pp.206-218, 2015.

F. Squitieri, M. Cannella, A. Porcellini, L. Brusa, M. Simonelli et al., Short-term effects of olanzapine in Huntington disease, Neuropsychiatry Neuropsychol Behav Neurol, vol.14, pp.69-72, 2001.

K. Duff, L. J. Beglinger, M. E. O'rourke, P. Nopoulos, H. L. Paulson et al., Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease, Ann Clin Psychiatry, vol.20, pp.1-3, 2008.

J. Read, R. Jones, G. Owen, B. R. Leavitt, A. Coleman et al., Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners, J Huntingtons Dis, vol.2, pp.159-75, 2013.

T. Patzold and M. Brüne, Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline, Neuropsychiatry Neuropsychol Behav Neurol, vol.15, pp.216-225, 2002.

A. Jhanjee, K. S. Anand, and B. K. Bajaj, Hypersexual features in Huntington's disease, Singapore Med J, vol.52, pp.131-134, 2011.

A. Tavares and F. M. Volpe, Cyproterone for treatment of hypersexuality in an elderly Huntington's disease patient, Prog Neuropsychopharmacol Biol Psychiatry, vol.32, pp.1994-1999, 2008.

S. S. Rich and F. Ovsiew, Leuprolide acetate for exhibitionism in Huntington's disease, Mov Disord, vol.9, pp.353-360, 1994.

D. M. Blass, M. Steinberg, I. Leroi, and C. G. Lyketsos, Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease, Am J Psychiatry, vol.158, pp.1966-72, 2001.

D. Paleacu, M. Anca, N. Giladi, E. S. Cankurtaran, E. Ozalp et al., Clinical experience with risperidone and memantine in the treatment of Huntington's disease, Acta Neurol Scand, vol.105, pp.1353-1358, 2002.

S. Madhusoodanan, R. Brenner, M. D. Sindagi, J. Brafman, and I. , Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study, Ann Clin Psychiatry, vol.10, pp.117-137, 1998.

S. Madhusoodanan and R. Brenner, Use of risperidone in psychosis associated with Huntington's disease, Am J Geriatr Psychiatry, vol.6, pp.347-356, 1998.

P. Oulis, I. Mourikis, G. Konstantakopoulos, S. G. Papageorgiou, and A. V. Kouzoupis, Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease, J Neuropsychiatry Clin Neurosci, vol.22, p.5, 2010.

M. A. Parsa, E. Szigethy, J. M. Voci, and H. Y. Meltzer, Risperidone in treatment of choreoathetosis of Huntington's disease, J Clin Psychopharmacol, vol.17, pp.134-139, 1997.

N. Vallette, O. Gosselin, and J. P. Kahn, Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case, Encephale, vol.27, pp.169-71, 2001.

K. F. Yavuz, S. Ulusoy, and I. Alniak, Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease, J Neuropsychiatry Clin Neurosci, vol.25, p.31, 2013.

M. Alpay and W. J. Koroshetz, Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease, Psychosomatics, vol.47, pp.70-72, 2006.

D. P. Seitz and R. C. Millson, Quetiapine in the management of psychosis secondary to huntington's disease: a case report, Can J Psychiatry, vol.49, p.413, 2004.

M. Edlinger, K. Seppi, W. Fleischhacker, and A. Hofer, Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease, Int Clin Psychopharmacol, vol.28, pp.214-220, 2013.

M. Sajatovic, P. Verbanac, L. F. Ramirez, and H. Y. Meltzer, Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea, Neurology, vol.41, p.156, 1991.

W. Lin and Y. Chou, Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease, Am J Psychiatry, vol.165, pp.1207-1215, 2008.

T. Nakano, S. Ono, J. Yamaguchi, R. Sugimoto, N. Yamaguchi et al., Modified electroconvulsive therapy for the treatment of refractory schizophrenia-like psychosis associated with Huntington's disease, J Neurol, vol.260, pp.312-316, 2013.

S. Rej and R. Desautels, Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease, J Neuropsychiatry Clin Neurosci, vol.25, pp.33-37, 2013.

C. Korenyi and J. R. Whittier, Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin), Psychiatr Q, vol.41, pp.203-213, 1967.

E. Bellosta-diago, P. Pérez, J. , S. Lasaosa, S. Viloria-alebesque et al., Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease, Parkinsonism Relat Disord, vol.44, pp.95-100, 2017.

I. Arnulf, J. Nielsen, E. Lohmann, J. Schiefer, J. Schieffer et al., Rapid eye movement sleep disturbances in Huntington disease, Arch Neurol, vol.65, pp.482-490, 2008.

V. Cochen, J. D. Degos, and A. C. Bachoud-lévi, Efficiency of carbamazepine in the treatment of micturitional disturbances in Huntington disease, Neurology, vol.55, p.1934, 2000.

D. Lewis, J. Fiske, and A. Dougall, Access to special care dentistry, part 7. Special care dentistry services: seamless care for people in their middle years-part 1, Br Dent J, vol.205, pp.305-322, 2008.

G. Manley, H. Lane, A. Carlsson, B. Ahlborg, Å. Mårtensson et al., Guideline for oral healthcare of adults with Huntington's disease, Neurodegener Dis Manag, vol.2, pp.55-65, 2012.

C. A. Boyle, C. Frölander, and G. Manley, Providing dental care for patients with Huntington's disease. Dent Update, vol.35, pp.333-339, 2008.

D. O. Moline and D. R. Iglehart, Huntington's chorea: review and case report, Gen Dent, vol.33, pp.131-134, 1985.

C. F. Cangemi and R. J. Miller, Huntington's disease: review and anesthetic case management, Anesth Prog, vol.45, pp.150-153, 1998.

S. Sciacca, M. Favellato, M. Madonna, D. Metro, M. Marano et al., Early enteric neuron dysfunction in mouse and human Huntington disease, Parkinsonism Relat Disord, vol.34, pp.73-77, 2017.

A. Brotherton, L. Campos, A. Rowell, V. Zoia, S. A. Simpson et al., Nutritional management of individuals with Huntington's disease: nutritional guidelines, Neurodegener Dis Manage, vol.2, pp.33-43, 2012.

A. Trejo, R. M. Tarrats, M. E. Alonso, M. Boll, A. Ochoa et al., Assessment of the nutrition status of patients with Huntington's disease, Nutrition, vol.20, pp.192-198, 2004.

E. Cubo, K. M. Shannon, D. Tracy, J. A. Jaglin, B. A. Bernard et al., Effect of donepezil on motor and cognitive function in Huntington disease, Neurology, vol.67, pp.1268-71, 2006.

N. A. Leopold and M. C. Kagel, Dysphagia in Huntington's disease, Arch Neurol, vol.42, pp.57-60, 1985.

M. A. Nance and G. Sanders, Characteristics of individuals with Huntington disease in long-term care, Mov Disord, vol.11, pp.542-550, 1996.

A. Trejo, M. Boll, M. E. Alonso, A. Ochoa, and L. Velásquez, Use of oral nutritional supplements in patients with Huntington's disease, Nutrition, vol.21, pp.889-94, 2005.

V. Popovic, M. Svetel, M. Djurovic, S. Petrovic, M. Doknic et al., Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease, Eur J Endocrinol, vol.151, pp.451-456, 2004.

J. Rivadeneyra, E. Cubo, C. G. Polo, N. Mariscal, S. Calvo et al., J14 mediterranean diet and nutritional composition of patients with Huntington's disease. Spanish multicenter study of the European group for Huntington's disease, J Neurol Neurosurg Psychiatry, pp.69-70, 2014.

E. Cubo, J. Rivadeneyra, N. Mariscal, D. Armesto, A. Mateos et al., The relationship between dietary intake, nutrition status and Huntington's disease severity (P1.050), Neurology, vol.4, pp.78-85, 2014.

A. Reyes, T. Cruickshank, K. Nosaka, and M. Ziman, Respiratory muscle training on pulmonary and swallowing function in patients with Huntington's disease: a pilot randomised controlled trial, Clin Rehabil, vol.29, pp.961-73, 2015.

M. Dean and V. W. Sung, Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease, Drug Des Devel Ther, vol.12, pp.313-322, 2018.

. Huntington-study-group, S. Frank, C. M. Testa, D. Stamler, E. Kayson et al., Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial, JAMA, vol.316, pp.40-50, 2016.

M. Busse, L. Quinn, C. Drew, M. Kelson, R. Trubey et al., Physical activity self-management and coaching compared to social interaction in Huntington disease: results from the ENGAGE-HD randomized, controlled pilot feasibility trial, Phys Ther, vol.97, pp.625-664, 2017.

S. Frese, J. A. Petersen, M. Ligon-auer, S. M. Mueller, V. Mihaylova et al., Exercise effects in Huntington disease, J Neurol, vol.264, pp.32-41, 2017.

S. M. Mueller, S. M. Gehrig, J. A. Petersen, S. Frese, V. Mihaylova et al., Effects of endurance training on skeletal muscle mitochondrial function in Huntington disease patients, Orphanet J Rare Dis, vol.19, p.184, 2017.

M. Wallace, N. Downing, S. Lourens, J. Mills, J. Kim et al., Is there an association of physical activity with brain volume, behavior, and day-to-day functioning? A cross sectional design in prodromal and early huntington disease

, PLoS Curr, vol.8, 2016.

N. E. Fritz, M. Busse, K. Jones, H. Khalil, and L. Quinn, Members of the Physiotherapy Working Group of the European Huntington's Disease Network. A classification system to guide physical therapy management in huntington disease: a case series, J Neurol Phys Ther, vol.41, pp.156-63, 2017.

, Disease Network (EHDN) during the completion of the work, and received honoraria for the duties involved in this position. AR received reimbursements as Co-Chair and Chair of the EHDN. RR is the owner of the George-HuntingtonInstitut GmbH and the QuantisMedis GmbH, Conflict of Interest Statement: J-MB was chair of the European Huntington's